Literature DB >> 9557727

Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells.

S Imai1, J Nishikawa, K Takada.   

Abstract

We show clear evidence for direct infection of various human epithelial cells by Epstein-Barr virus (EBV) in vitro. The successful infection was achieved by using recombinant EBV (Akata strain) carrying a selective marker gene but without any other artificial operations, such as introduction of the known EBV receptor (CD21) gene or addition of polymeric immunoglobulin A against viral gp350 in culture. Of 21 human epithelial cell lines examined, 18 became infected by EBV, as ascertained by the detection of EBV-determined nuclear antigen (EBNA) 1 expression in the early period after virus exposure, and the following selection culture easily yielded a number of EBV-infected clones from 15 cell lines. None of the human fibroblasts and five nonhuman-derived cell lines examined was susceptible to the infection. By comparison, cocultivation with virus producers showed approximately 800-fold-higher efficiency of infection than cell-free infection did, suggesting the significance of direct cell-to-cell contact as a mode of virus spread in vivo. Most of the epithelial cell lines infectable with EBV were negative for CD21 expression at the protein and mRNA levels. The majority of EBV-infected clones established from each cell line invariably expressed EBNA1, EBV-encoded small RNAs, rightward transcripts from the BamHI-A region of the virus genome, and latent membrane protein (LMP) 2A, but not the other EBNAs or LMP1. This restricted form of latent viral gene expression, which is a central issue for understanding epithelial oncogenesis by EBV, resembled that seen in EBV-associated gastric carcinoma and LMP1-negative nasopharyngeal carcinoma. The results indicate that direct infection of epithelial cells by EBV may occur naturally in vivo, and this could be mediated by an unidentified, epithelium-specific binding receptor for EBV. The EBV convertants are viewed, at least in terms of viral gene expression, as in vitro analogs of EBV-associated epithelial tumor cells, thus facilitating analysis of an oncogenic role(s) for EBV in epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557727      PMCID: PMC109667          DOI: 10.1128/JVI.72.5.4371-4378.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism.

Authors:  J W Sixbey; Q Y Yao
Journal:  Science       Date:  1992-03-20       Impact factor: 47.728

2.  Epstein-Barr virus infection and replication in a human epithelial cell system.

Authors:  Q X Li; L S Young; G Niedobitek; C W Dawson; M Birkenbach; F Wang; A B Rickinson
Journal:  Nature       Date:  1992-03-26       Impact factor: 49.962

3.  Establishment of three human renal cell carcinoma cell lines (SMKT-R-1, SMKT-R-2, and SMKT-R-3) and their characters.

Authors:  N Miyao; T Tsukamoto; Y Kumamoto
Journal:  Urol Res       Date:  1989

4.  Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease.

Authors:  L Young; C Alfieri; K Hennessy; H Evans; C O'Hara; K C Anderson; J Ritz; R S Shapiro; A Rickinson; E Kieff
Journal:  N Engl J Med       Date:  1989-10-19       Impact factor: 91.245

5.  Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells.

Authors:  C Cochet; D Martel-Renoir; V Grunewald; J Bosq; G Cochet; G Schwaab; J F Bernaudin; I Joab
Journal:  Virology       Date:  1993-11       Impact factor: 3.616

6.  Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein.

Authors:  S Imai; S Koizumi; M Sugiura; M Tokunaga; Y Uemura; N Yamamoto; S Tanaka; E Sato; T Osato
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

7.  Epstein-Barr virus-associated gastric carcinoma and Epstein-Barr virus infection of the stomach.

Authors:  M Fukayama; Y Hayashi; Y Iwasaki; J Chong; T Ooba; T Takizawa; M Koike; S Mizutani; M Miyaki; K Hirai
Journal:  Lab Invest       Date:  1994-07       Impact factor: 5.662

8.  Establishment of a new human cancer cell line secreting protease nexin-II/amyloid beta protein precursor derived from squamous-cell carcinoma of lung.

Authors:  H Itoh; H Kataoka; H Koita; K Nabeshima; T Inoue; K Kangawa; M Koono
Journal:  Int J Cancer       Date:  1991-09-30       Impact factor: 7.396

9.  Coupled transcription of Epstein-Barr virus latent membrane protein (LMP)-1 and LMP-2B genes in nasopharyngeal carcinomas.

Authors:  F Chen; L F Hu; I Ernberg; G Klein; G Winberg
Journal:  J Gen Virol       Date:  1995-01       Impact factor: 3.891

10.  Epstein-Barr virus-associated gastric adenocarcinoma.

Authors:  D Shibata; L M Weiss
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

View more
  112 in total

1.  Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes.

Authors:  Y Chang; C H Tung; Y T Huang; J Lu; J Y Chen; C H Tsai
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 2.  Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  G Niedobitek
Journal:  Mol Pathol       Date:  2000-10

3.  The cis-acting family of repeats can inhibit as well as stimulate establishment of an oriP replicon.

Authors:  E R Leight; B Sugden; E R Light
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

4.  Establishment of an oriP replicon is dependent upon an infrequent, epigenetic event.

Authors:  E R Leight; B Sugden
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

5.  Epstein-Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin.

Authors:  Jie Lu; Masanao Murakami; Subhash C Verma; Qiliang Cai; Sabyasachi Haldar; Rajeev Kaul; Mariusz A Wasik; Jaap Middeldorp; Erle S Robertson
Journal:  Virology       Date:  2010-11-19       Impact factor: 3.616

6.  Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands.

Authors:  A Janz; M Oezel; C Kurzeder; J Mautner; D Pich; M Kost; W Hammerschmidt; H J Delecluse
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 7.  Epstein-Barr virus and gastric carcinoma.

Authors:  K Takada
Journal:  Mol Pathol       Date:  2000-10

8.  Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta.

Authors:  Yao Chang; Heng-Huan Lee; Shih-Shin Chang; Tsuey-Ying Hsu; Pei-Wen Wang; Yu-Sun Chang; Kenzo Takada; Ching-Hwa Tsai
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

9.  Modeling the dynamics of virus shedding into the saliva of Epstein-Barr virus positive individuals.

Authors:  Giao T Huynh; Libin Rong
Journal:  J Theor Biol       Date:  2012-06-07       Impact factor: 2.691

10.  Host SHP1 phosphatase antagonizes Helicobacter pylori CagA and can be downregulated by Epstein-Barr virus.

Authors:  Priya Saju; Naoko Murata-Kamiya; Takeru Hayashi; Yoshie Senda; Lisa Nagase; Saori Noda; Keisuke Matsusaka; Sayaka Funata; Akiko Kunita; Masayuki Urabe; Yasuyuki Seto; Masashi Fukayama; Atsushi Kaneda; Masanori Hatakeyama
Journal:  Nat Microbiol       Date:  2016-03-14       Impact factor: 17.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.